Afobazol tablets 10mg №20×3

NameAfobazol tabl. The main active substance Morpholinoethylthioethoxybenzimidazole Form of release tablets Dosage 10 mg Pharmacodynamics Afobazol® is a selective non-benzodiazepine anxiolytic. Acting on sigma-1 receptors in the nerve cells of the brain, Afobazole® stabilizes GABA / benzodiazepine receptors and restores their sensitivity to endogenous inhibitory mediators. Afobazole® also increases the bioenergy potential of nerve cells and protects them from damage (has a neuroprotective effect). The action of the drug is realized mainly in the form of a combination of anxiolytic (anti-anxiety) and mild stimulating (activating) effects. Afobazole® reduces or eliminates anxiety (concern, bad forebodings, fears, irritability), tension (shyness, tearfulness, anxiety, inability to relax, insomnia, fear), somatic manifestations of anxiety (muscular, sensory, cardiovascular, respiratory, gastrointestinal -intestinal symptoms), autonomic disorders (dry mouth, sweating, dizziness), cognitive disorders (difficulty concentrating, impaired memory). Especially indicated is the use of the drug in persons with predominantly asthenic personality traits in the form of anxious suspiciousness, uncertainty, increased vulnerability and emotional lability, a tendency to emotional stress reactions. The effect of the drug develops on the 5-7th day of treatment. The maximum effect is achieved by the end of 4 weeks of treatment and persists after the end of treatment for an average of 1-2 weeks. Afobazol® does not cause muscle weakness, drowsiness and does not have a negative effect on concentration and memory. With its use, drug dependence is not formed and the “withdrawal” syndrome does not develop. PharmacokineticsAfter oral administration, Afobazol® is well and rapidly absorbed from the gastrointestinal tract. The maximum concentration of the drug in plasma (Cmax) is 0.130 ± 0.073 μg / ml; the time to reach the maximum concentration (Tmax) is 0.85±0.13 hours. Metabolism: Afobazole® undergoes a “first pass effect” through the liver, the main directions of metabolism are hydroxylation along the aromatic ring of the benzimidazole cycle and oxidation along the morpholine fragment. Afobazole® is intensively distributed over well-vascularized organs, it is characterized by rapid transfer from the central pool (blood plasma) to the peripheral (highly vascularized organs and tissues). The half-life of Afobazol® when taken orally is 0.82 ± 0.54 hours. The short half-life is due to the intensive biotransformation of the drug and the rapid distribution from blood plasma to organs and tissues. The drug is excreted mainly in the form of metabolites and partly unchanged in the urine and feces. With prolonged use does not accumulate in the body. Indications for use AFOBAZOL® is used in adults with anxiety conditions: generalized anxiety disorders, neurasthenia, adaptation disorders, in patients with various somatic diseases (bronchial asthma, irritable bowel syndrome, systemic lupus erythematosus, coronary heart disease, hypertension, arrhythmias), dermatological, oncological and other diseases. In the treatment of sleep disorders associated with anxiety, neurocirculatory dystonia, premenstrual syndrome, alcohol withdrawal syndrome, to alleviate the “withdrawal” syndrome when quitting smoking. The use of the drug Afobazol® for the treatment of generalized anxiety disorder is permissible only as prescribed by the attending physician. Dosage and administration It is used orally, after meals. Optimal single doses – 10 mg; daily – 30 mg, divided into 3 doses during the day. The duration of the course of the drug is 2-4 weeks. If necessary, on the recommendation of a doctor, the daily dose of the drug can be increased to 60 mg, and the duration of treatment up to 3 months. Use during pregnancy and lactation The use of the drug during pregnancy and lactation is contraindicated, because. study of the safety of the drug in pregnant and lactating women has not been conducted. In experimental studies, evidence of reproductive toxicity was not obtained. Interaction with other drugs Afobazole® does not interact with ethanol and does not affect the hypnotic effect of thiopental. Enhances the anticonvulsant effect of carbamazepine. It causes an increase in the anxiolytic action of diazepam. ContraindicationsIndividual intolerance to the drug. Galactose intolerance, lactase deficiency or glucose-galactose malabsorption. Pregnancy, lactation. Children’s age up to 18 years. Composition Per tablet: Active ingredient: fabomotizole (fabomotizole dihydrochloride) – 10 mg. Excipients: potato starch – 48 mg, microcrystalline cellulose – 35 mg, lactose monohydrate – 48.5 mg, medium molecular weight povidone (medium molecular weight polyvinylpyrrolidone, collidone 25) – 7 mg, magnesium stearate – 1.5 mg. Overdose In case of significant overdose and intoxication, the development of a sedative effect and increased drowsiness without manifestations of muscle relaxation. As an emergency, caffeine 20% solution is used in ampoules of 1.0 ml 2-3 times a day subcutaneously. Side effects Allergic reactions are possible. Rarely – headache, which usually resolves on its own and does not require discontinuation of the drug. Storage conditionsStore at a temperature not exceeding 25 °C. Keep out of the reach of children. Store the drug in its original packaging to protect from light and moisture. Buy Afobazol tablets 10mg No. 20×3 Price for Afobazole tablets 10mg No. 20×3